Loxapine versus chlorpromazine in paranoid schizophrenia: a double-blind study.
Newly admitted paranoid schizophrenic patients (N = 68) were treated with either loxapine or chlorpromazine for up to 4 weeks. Mean maximum dosages were 84 mg/day of loxapine and 820 mg/day of chlorpromazine. Loxapine showed efficacy superior to that of chlorpromazine, confirming earlier retrospective findings. Adverse reactions were also less troublesome with loxapine.
D000328:Adult; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D002746:Chlorpromazine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003989:Dibenzoxazepines / Q000627:therapeutic use*; D004244:Dizziness / Q000139:chemically induced; D004311:Double-Blind Method; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D005260:Female; D006760:Hospitalization; D006801:Humans; D007024:Hypotension, Orthostatic / Q000139:chemically induced; D008152:Loxapine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D012563:Schizophrenia, Paranoid / Q000188:drug therapy* / Q000523:psychology
D003989:Dibenzoxazepines; D008152:Loxapine; D002746:Chlorpromazine